Leerink Partners将Twist Bioscience评级上调至"跑赢大盘",目标价提升至70美元

美股速递
May 05

投资银行Leerink Partners宣布将合成生物学公司Twist Bioscience Corp(TWST)的股票评级从"与大市持平"上调至"跑赢大盘",同时将其目标股价从55美元大幅提升至70美元。

此次评级调整显示该机构对Twist Bioscience未来增长前景的乐观预期。目标价27%的上调幅度凸显了Leerink Partners对公司基本面改善和业务发展潜力的认可。

作为专注于DNA合成技术的生物科技企业,Twist Bioscience近年来在基因编辑、药物研发等领域的商业化应用持续拓展,获得资本市场密切关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10